口腔乾燥症治療市場

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) Global Health Observatory, American Dental Association (ADA), European Association of Oral Medicine (EAOM), Sjögren's Syndrome Foundation, American Academy of Oral Medicine (AAOM), International Society for Oral Oncology (ISOO), National Institute of Dental and Craniofacial Research (NIDCR), EU Eurostat Health Database, OECD Health Statistics, IQVIA National Prescription Audit, Symphony Health Solutions, and national health ministry reports from key markets including the US Department of Health and Human Services (HHS), UK National Health Service (NHS), Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA) Japan, and National Medical Products Administration (NMPA) China. These sources were used to collect prescription data, regulatory approval timelines, clinical safety and efficacy studies, epidemiological statistics on Sjögren's syndrome and radiation-induced xerostomia, demographic trends in aging populations, and competitive landscape analysis for salivary substitutes, salivary stimulants (pilocarpine, cevimeline), anticholinergics, and emerging drug formulations.

During the primary research process, both supply-side and demand-side stakeholders were interviewed to gather qualitative and quantitative insights. Supply-side sources included CEOs, VPs of Product Development, heads of regulatory affairs, commercial directors, and portfolio managers from pharmaceutical companies that make drugs for xerostomia, oral care product companies, and contract manufacturing organizations (CMOs). Demand-side sources included board-certified oral medicine specialists, head and neck oncologists, radiation oncologists, rheumatologists (Sjögren's specialists), hospital pharmacy directors, retail pharmacy procurement managers, medical affairs professionals from hospital systems, and formulary decision-makers from academic medical centers, community hospitals, specialty clinics, and cancer treatment centers. Primary research confirmed market segmentation across drug types (salivary substitutes, stimulants, anticholinergics), confirmed product pipeline timelines for novel muscarinic agonists and gene therapies, and gathered insights on clinical adoption patterns, pricing strategies, reimbursement dynamics for prescription vs. over-the-counter products, and patient adherence challenges.

Primary Respondent Breakdown:

By Designation: C-level Primaries (28%), Director Level (35%), Others (37%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Global market valuation was derived through revenue mapping, prescription volume analysis, and procedure-based demand modeling. The methodology included:

Identification of 40+ key manufacturers and marketers across North America, Europe, Asia-Pacific, and Latin America specializing in prescription xerostomia treatments and over-the-counter oral care products

Product mapping across salivary substitutes (artificial saliva sprays, gels, rinses), salivary stimulants (pilocarpine, cevimeline), anticholinergics, and emerging drug categories

Analysis of reported and modeled annual revenues specific to xerostomia therapeutic portfolios, including both pharmaceutical and consumer health divisions

Coverage of manufacturers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (prescription volume × ASP by country, patient prevalence × treatment rates × therapy cost) and top-down (manufacturer revenue validation, industry association estimates) approaches to derive segment-specific valuations across drug type, route of administration (oral, sublingual, topical, injection), disease indication (Sjögren's syndrome, radiation therapy-induced, medication-induced), and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies)